Evolution of functional class,biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice

Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart failure and reduced ejection fraction that started treatment with sacubitril/valsartan. Results: 149 patients (70.7 +/- 9.6years) were included. At baseline, 83.9, 15.4 and 0.7% were taking sacubitril/valsartan 24/26, 49/51 and 97/103mg, respectively. After 316.1 +/- 155.9days, these numbers moved to 38.9, 39.6, 12.8% (8.7% discontinued). Sacubitril/valsartan improved functional class (from 2.3 +/- 0.6 to 1.8 +/- 0.5; p <0.001), increased ejection fraction (from 31.2 +/- 7.0 to 37.3 +/- 10.5%; p <0.001) and reduced NT-proBNP (from 3884 +/- 4871 to 1975.3 +/- 3006.6pg/ml; p =0.0001). Rates of any event, cardiovascular death and heart failure hospitalization/decompensation were 13.2 events/100 patient-years. Conclusion: Sacubitril/valsartan is effective and safe in routine practice.